title: A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib.
authors.affiliation: Medical Oncology 2, Istituto Oncologico Veneto, Padua, Italy; Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Frega
authors.affiliation: Medical Oncology 2, Istituto Oncologico Veneto, Padua, Italy; Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy.
authors.forename: PierFranco
authors.initials: P
authors.lastname: Conte
authors.affiliation: Surgical Pathology Unit, Department of Medicine, University of Padua, Padua, Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Fassan
authors.affiliation: Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Polo
authors.affiliation: Medical Oncology 2, Veneto Oncological Institute, Padua, Italy. Electronic address: giulia.pasello@ioveneto.it.
authors.forename: Giulia
authors.initials: G
authors.lastname: Pasello
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000077716:Afatinib; D000368:Aged; D066246:ErbB Receptors / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D009154:Mutation; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000077716:Afatinib; D066246:ErbB Receptors; D011799:Quinazolines; D011838:Radiation-Sensitizing Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; C512478:EGFR protein, human; C508053:ERBB2 protein, human